Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 68

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Anti-myelin-associated glycoprotein associated polyneuropathy

Not yet recruiting

Study of rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Glioblastoma multiforme

Not yet recruiting

Study on the Effectiveness of Valganciclovir for Patients with Glioblastoma

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Valganciclovir
  • Sponsor:Karolinska Institutet

Dementia Alzheimer's type

Not recruiting

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Migraine

Not recruiting

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Therapeutics GmbH

Migraine

Not recruiting

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Therapeutics GmbH

Migraine

Not recruiting

Study of IPN10200 compared to placebo for prevention of episodic or chronic migraine in adults

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Post herpetic neuralgia

Not recruiting

Study of aneratrigine mesilate (iN1011-N17-02) to find the best dose for treating pain in adults with post-herpetic neuralgia

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:iN Therapeutics Co. Ltd.

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium chloride solution 0.9%
  • Sponsor:Pfizer Inc.

Muscle spasticity

Not recruiting

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Neuralgia+1

Not recruiting

Study on LY3848575 for Reducing Pain in Patients with Distal Sensory Polyneuropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3848575
  • Sponsor:Eli Lilly & Co.

Amyotrophic lateral sclerosis

Not recruiting

Study on the Effects of ION363 for Patients with Amyotrophic Lateral Sclerosis with Fused in Sarcoma Mutations

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ulefnersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Post-acute COVID-19 syndrome+1

Not recruiting

Study on the Effects and Safety of Ginkgo Biloba Extract in Patients with Cognitive Impairment After COVID-19

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.